{"prompt": "['2017N331008_06', 'CONFIDENTIAL', '208090', 'Pozniak A, Markowitz M, Mills A, et. al. Switching to coformulated elvitegravir,', 'cobicistat, emtricitabine, and tenofovir versus continuation of non-nucleoside reverse', 'transcriptase inhibitor with emtricitabine and tenofovir in virologically suppressed adults', 'with HIV (STRATEGY-NNRTI): 48 week results of a randomised, open-label, phase 3b', 'non-inferiority trial. Lancet Infect Dis. 2014;14:590-99.', 'Sato T. On the variance estimator for the Mantel-Haenszel risk difference.', 'Biometrics.1989;45:1323-24.', 'Solomon A, Tennakoon S, Leeansyah E, et al. (2014) No Difference in the Rate of', 'Change in Telomere Length or Telomerase Activity in HIV-Infected Patients after Three', 'Years of Darunavir/Ritonavir with and without Nucleoside Analogues in the MONET', 'Trial. PLoS ONE 9(11): e109718. doi:10.1371/journal.pone.0109718. Available at:', 'http://journals.plos.org/plosone/article/asset?id=10.1371/journal.pone.0109718.PDF.', 'Accessed February 8, 2017.', 'Stella-Ascariz N, Montejano R, Pintado-Berninches P, et al. Brief Report: Differential', 'effects of tenofovir, abacavir, emtricitabine, and darunavir on telomerase activity in vitro.', 'J. Acquir Immune Defic Syndr 2017;74:91-94', 'Taiwo BO, Marconi VC, Berzins B, Moser CB, Nyaku AN, Fichtenbaum CJ, et al.', 'Dolutegravir Plus Lamivudine Maintains Human Immunodeficiency Virus-1 Suppression', 'Through Week 48 in a Pilot Randomized Trial. Clin Infect Dis. 2018 May', '17;66(11):1794-1797.', 'Trottier B, Lake J, Logue K, et. al. Switching to Abacavir/Dolutegravir/Lamivudine', 'Fixed Dose Combination (ABC/DTG/3TC FDC) from a PI, INI or NNRTI Based', 'Regimen Maintains HIV Suppression. ICAAC/ICC 2015, San Diego, CA, USA, Sep 17-', '21, 2015.  2015-LB-3271-ASM-ICAAC.', 'U.S. Department of Health and Human Services, Food and Drug Administration, Center', 'for Drug Evaluation and Research (CDER). Guidance for Industry: Human', 'Immunodeficiency Virus-1 Infection: Developing Antiretroviral Drugs for Treatment.', 'November 2015 Available at:', 'ittp://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidanc', 'es/ucm355128.pdf. Accessed February 8, 2017.', 'U.S. Department of Health and Human Services. Food and Drug Administration (FDA). FDA', 'Guidance on Conduct of Clinical Trials of Medical Products during COVID-19 Pandemic -', 'Guidance for Industry, Investigators, and Institutional Review Boards. March 2020.', 'Available at: https://www.fda.gov/media/136238/download. Accessed April 6, 2020.', 'van Wyk J, Ajana F, Bisshop F, De Wit S, et. al. Efficacy and Safety of Switching to', 'Dolutegravir/Lamivudine Fixed-Dose Two-Drug Regimen Versus Continuing a', 'Tenofovir Alafenamide-Based Three- or Four-Drug Regimen for Maintenance of', 'Virologic Suppression in Adults With HIV-1: Phase 3, Randomized, Non-inferiority', 'TANGO Study. Clin Infect Dis. 2020 Jan 6. pii: ciz1243. doi: 10.1093/cid/ciz1243', '84']['2017N331008_06', 'CONFIDENTIAL', '208090', 'Walmsley S, Baumgarten A, Berenguer J, et al. Dolutegravir Plus Abacavir/Lamivudine', 'for the Treatment of HIV-1 Infection in Antiretroviral Therapy-Naive Patients: Week 96', 'and Week 144 Results from the SINGLE Randomized Clinical Trial. J Acquir Immune', 'Defic Syndr. 2015;70:515-519.', 'Walmsley SL, Antela A, Clumeck N, et. al. Dolutegravir plus abacavir-lamivudine for', 'the treatment of HIV-1 infection. N Engl J Med. 2013;369(19) 1807-18.', 'Wensing AM, Calvez V, G\u00fcnthard HF, et. al. IAS-USA. Topics in Antiviral Medicine.', 'Special Contribution. Update of the drug resistance mutations in HIV-1. 2017 Drug', 'Resistance Mutations Update. 2017: 24(4):132-41. December 2016/January 2017.', 'Woodcock A, Bradley C. Validation of the HIV treatment satisfaction questionnaire', '(HIVTSQ). Qual Life Res. 2001;10(6):517-531', 'Woodcock A, Bradley C. Validation of the revised 10-item HIV Treatment Satisfaction', 'Questionnaire status version and new change version. Value Health. 2006;9(5):320-333.', '85']\n\n###\n\n", "completion": "END"}